Kentarou Kudou
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Japanese Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: A Phase 3, Open-label Clinical Trial.
Journal: Internal medicine (Tokyo, Japan)
Published: August 19, 2026
Pharmacokinetics, safety and tolerability, and efficacy of hyaluronidase-facilitated subcutaneous immunoglobulin 10% (HyQvia®) in Japanese patients with primary immunodeficiency diseases.
Journal: Immunological medicine
Published: February 13, 2026
Efficacy and safety of brigatinib after alectinib in patients with ALK-positive NSCLC: Integrated analysis of the ALTA-2 and J-ALTA studies.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 22, 2025
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 12, 2024
Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials.
Journal: Biological & pharmaceutical bulletin
Published: July 31, 2024
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Journal: International journal of clinical oncology
Published: January 17, 2023
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Journal: International journal of clinical oncology
Published: October 15, 2022
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Journal: International journal of clinical oncology
Published: May 13, 2022
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Journal: Journal of gastroenterology and hepatology
Published: November 03, 2021
Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D2 /D3 Receptor Antagonist: Phase I Single- and Multiple-Ascending Dose Studies in Healthy Japanese Participants.
Journal: Clinical pharmacology in drug development
Published: September 08, 2021
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
Journal: BMC women's health
Published: March 18, 2021
Last Updated: 09/26/2026